TY - JOUR
T1 - A phase I trial
T2 - Dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection
AU - Phillips, Gordon L.
AU - Bernstein, Steven H.
AU - Liesveld, Jane L.
AU - Abboud, Camille N.
AU - Becker, Michael W.
AU - Constine, Louis S.
AU - Ifthikharuddin, J. J.
AU - Loughner, John E.
AU - Milner, Laurie A.
AU - Vesole, David H.
AU - Friedberg, Jonathan W.
PY - 2011/7
Y1 - 2011/7
N2 - With the eventual goal of reducing relapse and thus improving overall survival in selected lymphoma patients, a Phase I study was performed using the cytoprotectant amifostine to permit safe dose-augmentation of melphalan in the carmustine (BCNU), etoposide, cytarabine (arabinosylcytosine), and melphalan (BEAM) regimen before autologous hematopoietic stem cell transplantation. Between 30 July 2003 and 25 November 2008, a total of 32 lymphoma patients were entered, of which 28 were evaluable. We found the melphalan dose in BEAM could be safely escalated to at least 260 mg/m2, a substantial increase from the usual dose of 140 mg/m2 in BEAM while the trial was terminated early due to poor accrual, no maximal tolerated dose or dose-limiting toxicity was found. A Phase II trial is planned.
AB - With the eventual goal of reducing relapse and thus improving overall survival in selected lymphoma patients, a Phase I study was performed using the cytoprotectant amifostine to permit safe dose-augmentation of melphalan in the carmustine (BCNU), etoposide, cytarabine (arabinosylcytosine), and melphalan (BEAM) regimen before autologous hematopoietic stem cell transplantation. Between 30 July 2003 and 25 November 2008, a total of 32 lymphoma patients were entered, of which 28 were evaluable. We found the melphalan dose in BEAM could be safely escalated to at least 260 mg/m2, a substantial increase from the usual dose of 140 mg/m2 in BEAM while the trial was terminated early due to poor accrual, no maximal tolerated dose or dose-limiting toxicity was found. A Phase II trial is planned.
KW - Amifostine
KW - Autologous stem cell
KW - Melphalan
KW - Phase I
KW - Regimen-related toxicity
UR - https://www.scopus.com/pages/publications/79958749844
U2 - 10.1016/j.bbmt.2010.11.003
DO - 10.1016/j.bbmt.2010.11.003
M3 - Article
C2 - 21074630
AN - SCOPUS:79958749844
SN - 1083-8791
VL - 17
SP - 1033
EP - 1042
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 7
ER -